On February 24, 2016 Nanomerics’ scientists reported they have demonstrated that encapsulating chemotherapy drugs within Nanomerics’ MET nanoparticles diverts the drug from the bone marrow, while enabling higher levels of drug to access the brain (Press release, Nanomerics, FEB 24, 2016, View Source [SID:1234509184]). Animals intravenously dosed with Nanomerics’ MET – lomustine formulations showed significantly improved survival rates when compared to the drug in solution and the effect of the drug on the bone marrow was comparable to the drug in solution. The work is described in a new paper published in Pharmaceutical Research View Source This data demonstrates the further utility of Nanomerics’ MET via the intravenous route. The MET formulation worked by enabling a higher dose of the hydrophobic drug lomustine to be administered and this higher dose did not result in higher levels of drug in the bone and liver, whereas levels of the drug in the brain were increased. The bone marrow is a major site of toxicity for alkylating agents such as lomustine and dose limiting myelosuppression compromises brain tumour therapy significantly.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nanomerics’ Chief Scientific Officer states, "this study provides evidence that Nanomerics’ MET nanoparticles are able to avoid the bone marrow and indeed the liver on intravenous administration and provide a method of administering a hydrophobic alkylating agent for the treatment of brain tumours."